Anagenic is trying to compound Gt20029 Treatment 3/10/2023
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
View this post in the Community →
Similar Community Posts Join
6 / 243 resultscommunity Pyrilutamide PHASE 2 Results just one months to go. Are you excited???🤩
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
community GT20029: The Cure to Hair Loss? Here's what we know
The conversation discusses GT20029 as a potential cure for hair loss and includes information on specific treatments used. Minoxidil, finasteride, and RU58841 are mentioned as related treatments.
community I interviewed Kintor: GT20029 Clinical Trial Pictures. As well as KX826.
GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.
community Reminder that Kintors Pyrilutamide results will be out this month
Kintor's Pyrilutamide results for hair loss treatment will be released soon. The treatment may replace current treatments like finasteride and minoxidil without systemic side effects.
community PYRILUTAMIDE PHASE 3 RESULTS : No statistical significance
The phase 3 trial results for Pyrilutamide showed no significant difference from the control treatment in increasing hair count, leading to the company halting its development. Users discussed their disappointment and skepticism about hair loss treatments, with some mentioning other treatments like Minoxidil, Finasteride, and RU58841.
community Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
Related Research
5 / 5 results
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research What's New in Therapy for Male Androgenetic Alopecia?

research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
research Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.

research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.